SAN DIEGO, September 4 /PRNewswire/ --

- Results Further Validate Lipidomic-Based Therapeutics as an Emerging
Area of Drug Discovery

Lpath, Inc. (OTC Bulletin Board: LPTN), the category leader in
therapeutic agents against bioactive lipids, reported positive results in
several murine models of human cancer and AMD with Lpathomab(TM), the
company's mouse monoclonal antibody against LPA (lysophosphatidic acid).
These results confirm the expected potent anti-angiogenic and anti-metastatic
actions of Lpathomab. Lpathomab was created using Lpath's proprietary
ImmuneY2(TM) platform technology.

Based on this positive outcome, Lpath will collaborate with DataMabs of
London, England, to humanize Lpathomab to create a lead antibody for
pre-clinical development.

LPA is a bioactive lipid long recognized as a significant promoter of
cancer-cell growth and metastasis in a broad range of tumor types, as well as
a significant contributor to neuropathic pain.

"Humanizing our Lpathomab antibody is a vital next step in moving the
project into the clinic," said Genevieve Hansen, Ph.D., Lpath's vice
president of research. "We've had great success in the past working with
DataMabs and look forward to working with them again on our Lpathomab
project."

This achievement with Lpathomab comes on the heels of Lpath's success
with its Sphingomab(TM) program. Sphingomab is an antibody against another
bioactive lipid, S1P. Lpath humanized the antibody in 2006 and plans to file
an IND in November of this year for the use of ASONEP(TM) (the systemic
formulation of humanized Sphingomab) for the treatment of cancer. It also
plans to file a second IND early next year for the use of iSONEP(TM) (the
ocular formulation of humanized Sphingomab) for the treatment of AMD. The
company plans to submit an IND filing for the use of humanized Lpathomab in
2009.

Dr. Roger Sabbadini, the founder and CSO of Lpath, commented, "These
exciting results provide further validation of lipidomic-based therapeutics
as an important new area of drug discovery. Lpath was one of the first
companies to recognize that bioactive-lipid-signaling molecules, like S1P and
LPA, could be excellent targets for rational drug design. By pursuing these
targets and demonstrating compelling efficacy, we've opened up an entire
class of lipidomic-based therapeutics for the treatment of cancer, diabetes,
neurodegenerative disorders, immune function, inflammation, pain, mental
disorders, and cardiovascular disease."

Scientists now believe that there are over 1,000 members of the
functional lipidome, each of which is a new potential target for therapeutic
intervention.

About Lpath:

Lpath, Inc., headquartered in San Diego, California, is the category
leader in lipidomics-based therapeutics, an emerging field of medical science
whereby bioactive signaling lipids are targeted for treating important human
diseases. ASONEP(TM) (the systemic formulation of humanized form of
Sphingomab(TM)) is an antibody against S1P that holds promise for the
treatment of cancer and other diseases. A second product candidate,
iSONEP(TM) (the ocular formulation of humanized Sphingomab), has demonstrated
superior results in various preclinical AMD and retinopathy models. Lpath's
third product candidate, Lpathomab(TM), is an antibody against LPA, a key
bioactive lipid that has been long recognized as a valid disease target. The
company's unique ability to generate novel antibodies against bioactive
lipids is based on its ImmuneY2(TM) drug-discovery engine, which the company
is using to add to its pipeline. For more information, visit
http://www.Lpath.com

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this
press release are forward looking and reflect numerous assumptions and
involve a variety of risks and uncertainties, many of which are beyond our
control and may cause actual results to differ materially from stated
expectations. For example, there can be no assurance that required clinical
trials will be successful, necessary regulatory approvals will be obtained,
or the proposed treatments will prove to be safe or effective. Actual results
may also differ substantially from those described in or contemplated by this
press release due to risks and uncertainties that exist in our operations and
business environment, including, without limitation, our limited experience
in the development of therapeutic drugs, our dependence upon proprietary
technology, our history of operating losses and accumulated deficits, our
reliance on research grants, current and future competition, and other risks
described from time to time in our filings with the Securities and Exchange
Commission. We undertake no obligation to release publicly the results of any
revisions to these forward-looking statements to reflect events or
circumstances arising after the date hereof.

Contact:

    Scott Pancoast                     Investor Relations
    +1-858-678-0800 x104               Liolios Group, Inc.
    spancoast@Lpath.com                Scott Liolios or Ron Both
    http://www.Lpath.com               +1-949-574-3860



Web site: http://www.lpath.com